dc.contributor.author | Yilmaz Ö. | |
dc.contributor.author | Özden M.G. | |
dc.contributor.author | Aydin F. | |
dc.contributor.author | Sentürk N. | |
dc.contributor.author | Cantürk T. | |
dc.contributor.author | Turanli A.Y. | |
dc.date.accessioned | 2020-06-21T09:27:40Z | |
dc.date.available | 2020-06-21T09:27:40Z | |
dc.date.issued | 2010 | |
dc.identifier.issn | 1300-2996 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12712/4129 | |
dc.description.abstract | Cetuximab, is an IgG1 chimeric monoclonal antibody type of epidermal growth factor receptor (EGFR). It is most commonly prescribed for metastatic colorectal cancer, administered alone or in combination with irinotecan-based chemotherapy regimens (Lee et al., 2008; Segaert et al., 2005; Segaert and Cutsem 2005; Scope et al., 2009). Acneiform eruption is the most common adverse effect with 80% of incidence (Segaert and Cutsem 2005; Lee et al., 2008). We report two cases of severe acneiform eruption induced by cetuximab with metastatic colorectal cancer. © 2010 OMU All rights reserved. | en_US |
dc.language.iso | eng | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Acneiform eruption | en_US |
dc.subject | Cetuximab | en_US |
dc.subject | Chemotherapy | en_US |
dc.subject | Colorectal cancer | en_US |
dc.subject | Irinotecan | en_US |
dc.subject | Side effect | en_US |
dc.title | Acneiform skin lesions associated with cetuximab therapy: Report of two cases | en_US |
dc.type | article | en_US |
dc.contributor.department | OMÜ | en_US |
dc.identifier.volume | 27 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 118 | en_US |
dc.identifier.endpage | 119 | en_US |
dc.relation.journal | Journal of Experimental and Clinical Medicine (Turkey) | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |